Efficacy of and Safety of Secukinumab in Psoriasis Vulgaris: A Prospective Study
Syeda Shahmoona Tirmizi, Tayyaba Iqbal, Saher Ather, Nadia Farooq, Maria Mansoor, Marium Asar, Naseema Kapadia & Qurrat Ul Ain · Journal of Pharmaceutical Research International · 2022
Objective: Psoriasis is an immune mediated inflammatory skin disorder that potentially requires lifelong management. Different therapies treating psoriasis have been recognized wherein Secukinumab is a fully humanized, IL-17A monoclonal antibody that has been approved by US Food...
Open access
Research Article
10.9734/jpri/2022/v34i35A36164